CLOVIS ONCOLOGY, INC. Inactive Instrument
Clovis Oncology, Inc.
Equities
CLVS.Q
US1894641000
Biotechnology & Medical Research
Presenter SpeechJames Scott (Analysts)Good morning, and welcome to day 3 of the 40th Annual JP...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and an indication specific to metastatic castration-resistant prostate cancer (mCRPC). Its FAP-2286 is a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP). It also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3).
| 1st Jan change | Capi. | |
|---|---|---|
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
